Working… Menu

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03829436
Recruitment Status : Recruiting
First Posted : February 4, 2019
Last Update Posted : August 6, 2021
Information provided by (Responsible Party):
Tempest Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 18, 2022
Estimated Study Completion Date : June 23, 2024